MedPath

Transcranial Direct Current Stimulation in a Smoking Cessation Trial

Phase 2
Withdrawn
Conditions
Nicotine Dependence
Interventions
Device: sham transcranial Direct Current Stimulation
Device: active transcranial Direct Current Stimulation
Registration Number
NCT01710410
Lead Sponsor
Centre for Addiction and Mental Health
Brief Summary

The purpose of this study is to determine the effectiveness of transcranial direct current stimulation (tDCS) plus nicotine patch as a viable smoking cessation program for nicotine dependent smokers.

Detailed Description

BACKGROUND: Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that involves the application of brief weak electric current to the scalp. tDCS may induce neuroplasticity, thereby engaging some of the same systems that figure prominently in the pathological neuroplasticity caused by addictive drugs.

OBJECTIVE: To assess whether tDCS delivered along with nicotine patch reliably increases a) quit rates, b) duration of abstinence, and c) percentage of participants abstinent at follow-up.

METHOD: Active (20min; 2mA) and sham (30sec; 2mA) stimulation will be applied to the dorsolateral prefrontal cortex (DLPFC) in both cerebral hemispheres.

HYPOTHESES:

1. Active tDCS (20-min; 2 mA) will increase abstinence in a standard smoking cessation protocol relative to a sham procedure.

2. The benefits of active left anodal stimulation (anode-left/cathode-right) to the DLPFC will be greater than of active tDCS in the reverse configuration (cathode-left/anode-right).

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • nicotine dependent
  • treatment-seeking
  • smoke minimum of 15 cigarettes per day
  • able to provide written informed consent
  • able and willing to attend weekly appointments, inter-treatment and follow-up assessment
  • able and willing to wear nicotine patch
Exclusion Criteria
  • currently taking GABA receptor agonists, NMDA receptor antagonists, dopamine receptor agonists/antagonists, SSRIs, L-dopa, anticholinergics
  • pregnancy or lactation
  • any serious medical condition requiring treatment or medication including high blood pressure, heart problems, asthma, epilepsy
  • brain/neurological injury/disease/disorder
  • skin disease
  • current DSM-IV Axis I psychiatric disorder
  • metal or medical device implants
  • current treatment for alcohol or drug use
  • current use of herbal/holistic preparations
  • current use of recreational drugs

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
DLPFC tDCSsham transcranial Direct Current StimulationSham transcranial Direct Current Stimulation (tDCS) delivered to the DLPFC. Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
DLPFC tDCS (left anode/right cathode)active transcranial Direct Current StimulationActive transcranial Direct Current Stimulation (tDCS) administered to the left DLPFC. Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
DLPFC tDCS (left cathode/right anode)active transcranial Direct Current StimulationActive transcranial Direct Current Stimulation (tDCS) administered to the right DLPFC. Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
Primary Outcome Measures
NameTimeMethod
Smoking CessationParticipants will be followed for the duration of the study, an expected average of 9 months.

Measure whether active tDCS increases abstinence in a standard smoking cessation protocol relative to a sham tDCS procedure

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Centre for Addiction and Mental Health (Nicotine Dependence Clinic)

🇨🇦

Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath